研究倫理審查委員會 103 度 第5 次會議 會議紀錄

20140821
153017:30
()()() ()





/
K-333
peretinoin

(PEGASYS® ) (ribavirin)

07/08
/

() 103/06/16~103/08/10
49 9 ( 2 5 2
) 14 ( 3 11 ) 13 ( 3
11 ) 12 ( 4 8 ) 1 (
1 )

101034
103024
103013
103010
100046
101095
102067
102025
102015
-
101095 35
9 14 13 0 12 1 49
() 103 6 16 ~103 8 10
44 ,

/
36
Tenofovir Disoproxil
FumarateTDF
Peginterferon α-2a

and Safety of Tenofovir
Disoproxil Fumarate (TDF) in
Subjects with HBeAg-Positive or

Efficacy of Tenofovir
versus Tenofovir Disoproxil
the Treatment of HBeAg Positive,
Chronic Hepatitis B.
Joint Asia Diabetes Evaluation
of death among hospice
diabetic nephropathy
of ageing for
A Phase 2,
tests (ALT and AST) in
HCV-positive subjects who have
been nonresponsive to prior
ribavirin





/Chi-Yi
Tenofovir Disoproxil
FumarateTDF
Peginterferon α-2a

and Safety of Tenofovir
Disoproxil Fumarate (TDF) in
Subjects with HBeAg-Positive or

Taiwan




2 diabetes


/Lu
Yin-Che


2014/8/7
- 1
- 2
()
(1)- 3
:- 5
:- 6

8 2 2 1
2 1
CYCH-IRB No.103027

2014/07/09 PI ,07/16

:
:

:
11 0 0 0
/ 0
—
*
:PI
*
Asunaprevir Daclatasvir Peginterferon α-2a (Pegasys)
Ribavirin (Copegus) (P/R) (QUAD)/

*
4 5 () 0
0 / 0
:
25 Tenofovir Alafenamide TAF B
e B
300 Tenofovir Disoproxil Fumarate TDF
/
2014/08/08PI
2. 2014 6 13 JIRB JIRB
3. 2014 1 22


:
3 6 0 0
/ 0
:
semaglutide
/

0 ; 0
; 0 ; 0
:
SAE/UP ()
103 06 16 ~103 08 10 SAE/UP
: